Dexcom stock holds near USD 89.71 after strong Q2

Dexcom Inc. (US2521311074) stock is trading near USD 89.71 on September 4, 2026, with a market cap of USD 33.85 billion. The latest quarterly update showed revenue of USD 1.31 billion and earnings of USD 0.70 a share, both ahead of consensus, according to MarketBeat.

Q2 numbers set the tone

MarketBeat said Dexcom reported USD 0.70 in EPS versus the USD 0.61 consensus estimate, a gap of USD 0.09. Revenue reached USD 1.31 billion in the quarter, up 13.1 percent from a year earlier, and net margin was 20.12 percent.

That mix matters because the stock now trades at 35.46 times earnings, with a PEG ratio of 1.50 and a beta of 1.42. The comparison is straightforward: revenue growth outpaced the broader medical device backdrop, while profitability stayed close to one-fifth of sales.

Consensus stays positive

MarketBeat also reported a consensus rating of Moderate Buy and an average target price of USD 88.71. For Dexcom stock, that puts the share price close to the average target and keeps valuation the central question after the latest quarter.

The stock opened at USD 89.71 on September 4, 2026, which is above the reported average target of USD 88.71. The move leaves little distance between the current quote and the Street view.

G7 remains the key product

Dexcom's continuous glucose monitoring business still centers on the G7 platform, which is the product investors watch for adoption, pricing and refill trends. The current quarter's USD 1.31 billion in revenue shows that the installed base is still translating into scale.

Market level and valuation

Dexcom stock opened at USD 89.71 on September 4, 2026, against a market cap of USD 33.85 billion. That leaves the valuation tied to execution more than to price momentum alone.